Orphazyme A/S (ORPHA.CO)
Copenhagen - Copenhagen Real-time price. Currency in DKK
Add to watchlist
As of 11:47AM CEST. Market open.
| Previous close | 2.1360 |
| Open | 2.1400 |
| Bid | 2.0580 x 0 |
| Ask | 2.1200 x 0 |
| Day's range | 2.0560 - 2.1400 |
| 52-week range | 1.1000 - 54.6500 |
| Volume | |
| Avg. volume | 211,130 |
| Market cap | 72.814M |
| Beta (5Y monthly) | 1.07 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
KemPharm (KMPH) Stock Up on Deal to Acquire Orphazyme for $12.8M
KemPharm (KMPH) inks deal to acquire Orphazyme A/S, which will add to its portfolio the latter's pipeline candidate, arimoclomol, being developed for treating Niemann-Pick disease type C. Shares rise.
- Zacks
Orphazyme (ORPH) Up on Plans of NDA Resubmission for Rare Drug
Orphazyme (ORPH) is looking to resubmit its NDA for arimoclomol to the FDA for the treatment of Niemann-Pick disease type C in the United States. Shares rise.
- Zacks
All You Need to Know About Orphazyme AS Sponsored ADR (ORPH) Rating Upgrade to Buy
Orphazyme AS Sponsored ADR (ORPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
© 2022 Yahoo. All rights reserved.
